Get the Stockscreener App
21.00
0.43%
-0.09
After Hours:
21.00
Oculis Holding Ag stock is traded at $21.00, with a volume of 77,929.
It is down -0.43% in the last 24 hours and up +20.69% over the past month.
Oculis Holding AG is a global biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis.
See More
Previous Close:
$21.09
Open:
$21.2
24h Volume:
77,929
Relative Volume:
2.78
Market Cap:
$916.91M
Revenue:
-
Net Income/Loss:
$-75.28M
P/E Ratio:
-10.52
EPS:
-1.9957
Net Cash Flow:
$-57.45M
1W Performance:
+13.18%
1M Performance:
+20.69%
6M Performance:
+25.37%
1Y Performance:
+41.03%
1-Day Range:
$20.82
$21.40
1-Week Range:
$18.52
$21.94
52-Week Range:
$14.00
$23.08
Oculis Holding Ag Stock (OCS) Company Profile
Compare OCS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
OCS
Oculis Holding Ag
|
21.00 | 1.10B | 0 | -75.28M | -57.45M | -1.9957 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.37 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.95 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
557.73 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
799.56 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
327.03 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Oculis Holding Ag Stock (OCS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-27-25 | Initiated | Needham | Buy |
| Dec-05-23 | Initiated | Chardan Capital Markets | Buy |
| Oct-05-23 | Initiated | Stifel | Buy |
| Jun-14-23 | Initiated | BofA Securities | Buy |
| Jun-12-23 | Initiated | H.C. Wainwright | Buy |
| Jun-08-23 | Initiated | Robert W. Baird | Outperform |
| May-10-23 | Initiated | Pareto | Buy |
| Apr-28-23 | Initiated | Wedbush | Outperform |
View All
Oculis Holding Ag Stock (OCS) Latest News
What recovery options are there for Oculis Holding AGOptions Play & Weekly Breakout Watchlists - newser.com
Oculis Holding AG Equity Warrant’s volatility index tracking explained2025 Support & Resistance & High Conviction Buy Zone Picks - newser.com
What’s the recovery path for long term holders of Oculis Holding AGPortfolio Value Summary & Daily Entry Point Alerts - newser.com
Using data tools to time your Oculis Holding AG Equity Warrant exitGlobal Markets & Expert Approved Trade Ideas - newser.com
How Oculis Holding AG stock compares to industry benchmarks2025 Growth vs Value & Long-Term Growth Plans - newser.com
Live market analysis of Oculis Holding AG Equity WarrantJuly 2025 Sector Moves & AI Enhanced Trading Alerts - newser.com
Why Oculis Holding AG Equity Warrant stock could outperform in 2025Profit Target & AI Based Trade Execution Alerts - newser.com
Leading vs lagging indicators on Oculis Holding AG performanceEarnings Risk Report & Precise Trade Entry Recommendations - newser.com
Will Oculis Holding AG stock gain from strong economyWeekly Stock Analysis & Community Consensus Picks - newser.com
Chardan Capital Issues Positive Estimate for Oculis Earnings - MarketBeat
Risk adjusted return profile for Oculis Holding AG analyzedPrice Action & Low Drawdown Momentum Ideas - newser.com
Using RSI to spot recovery in Oculis Holding AG Equity Warrant2025 Trading Recap & Low Risk High Reward Ideas - newser.com
Will Oculis Holding AG Equity Warrant price bounce be sustainableJuly 2025 Spike Watch & Weekly Market Pulse Alerts - newser.com
Sentiment analysis tools applied to Oculis Holding AGMarket Growth Report & Stepwise Entry/Exit Trade Alerts - newser.com
Why Oculis Holding AG (CR5) stock is favored by hedge fundsIPO Watch & Long-Term Capital Growth Strategies - newser.com
Chart based analysis of Oculis Holding AG trendsJuly 2025 Catalysts & Verified Momentum Stock Ideas - newser.com
Oculis Holding AG (OCS) Soars 6.3%: Is Further Upside Left in the Stock? - Yahoo Finance
Oculis' (OCS) Sell (D-) Rating Reaffirmed at Weiss Ratings - MarketBeat
Is Oculis Holding AG Equity Warrant stock entering bullish territoryJuly 2025 Drop Watch & Verified Technical Trade Signals - newser.com
Price action breakdown for Oculis Holding AG Equity WarrantEarnings Recap Summary & Consistent Return Investment Signals - newser.com
Will Oculis Holding AG (CR5) stock benefit from sector leadershipIPO Watch & Accurate Technical Buy Alerts - newser.com
Chardan Capital Forecasts Strong Price Appreciation for Oculis (NASDAQ:OCS) Stock - Defense World
Oculis Holding AG Equity Warrant stock momentum explainedFed Meeting & Daily Growth Stock Tips - newser.com
What recovery options are there for Oculis Holding AG Equity Warrant - newser.com
What to expect from Oculis Holding AG in the next 30 daysTrade Signal Summary & Smart Swing Trading Alerts - newser.com
Can volume confirm reversal in Oculis Holding AG2025 Price Momentum & Reliable Trade Execution Plans - newser.com
Applying chart zones and confluence areas to Oculis Holding AG Equity Warrant2025 Market WrapUp & Scalable Portfolio Growth Ideas - newser.com
Oculis (NASDAQ:OCS) Sees Large Volume Increase Following Analyst Upgrade - Defense World
Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities - GlobeNewswire
Chardan Research Adjusts Oculis Holding AG Price Target to $51 From $33, Maintains Buy Rating - MarketScreener
Oculis (NASDAQ:OCS) Price Target Raised to $51.00 - MarketBeat
Chardan Capital Maintains Oculis Holding (OCS) Buy Recommendation - Nasdaq
HC Wainwright Issues Positive Forecast for Oculis (NASDAQ:OCS) Stock Price - Defense World
Oculis (NASDAQ:OCS) Sees Unusually-High Trading Volume After Analyst Upgrade - MarketBeat
Oculis (NASDAQ:OCS) Given New $36.00 Price Target at HC Wainwright - MarketBeat
HC Wainwright & Co. Maintains Oculis Holding (OCS) Buy Recommendation - Nasdaq
Oculis stock price target raised to $36 from $33 at H.C. Wainwright - Investing.com
Oculis to launch PIONEER trials for privosegtor in acute optic neuritis and NAION - Ophthalmology Times
Oculis Advances Privosegtor into Registrational Trials for Neuro-Ophthalmology - TipRanks
Does Oculis Holding AG Equity Warrant show high probability of reboundJuly 2025 Rallies & Community Supported Trade Ideas - newser.com
Reversal indicators forming on Oculis Holding AG Equity Warrant stockEarnings Risk Summary & Weekly High Conviction Trade Ideas - newser.com
Oculis Advances Privosegtor Into Registrational Trials for Neuroprotective Therapy - MarketScreener
Will Oculis Holding AG Equity Warrant bounce back from current supportJuly 2025 Weekly Recap & Stepwise Entry/Exit Trade Alerts - newser.com
Why retail traders accumulate Oculis Holding AG (CR5) stockJuly 2025 Review & Weekly Breakout Watchlists - newser.com
Can trapped investors hope for a rebound in Oculis Holding AG Equity WarrantJuly 2025 Recap & Pattern Based Trade Signal System - newser.com
Oculis Accelerates Privosegtor into Registrational Trials in Acute Optic Neuritis, Pioneering the Path for a Potential First-in-class Neuroprotective Therapy - The Manila Times
Oculis Advances Privosegtor into Pivotal Development for Acute Optic Neuritis and NAION Following Positive FDA Meeting - Quiver Quantitative
Will Oculis Holding AG (CR5) stock sustain bullish trend into 2025Trade Risk Report & Risk Adjusted Buy and Sell Alerts - newser.com
3 pivotal trials: Oculis launches PIONEER program for Privosegtor after positive FDA meeting - Stock Titan
Brokerages Set Oculis Holding AG (NASDAQ:OCS) PT at $35.75 - Defense World
What machine learning models say about Oculis Holding AG2025 Top Gainers & Free High Return Stock Watch Alerts - newser.com
Oculis Holding Ag Stock (OCS) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.11%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):